文献速递血栓与止血

瑞舒伐他汀降低静脉血栓栓塞症患者凝血酶生成潜力:一项随机对照试验

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial.
PubMed 文献 · J Thromb Haemost · 2019-02-03

START试验将既往静脉血栓栓塞症(VTE)患者随机分为瑞舒伐他汀20 mg/日治疗4周组与无干预组,采用凝血酶生成试验检测。瑞舒伐他汀组内源性凝血酶潜力(ETP)平均降低10.4%、凝血酶峰值平均降低5%,在心血管危险因素和无诱因VTE亚组中降低更明显。

要点

  • 瑞舒伐他汀20 mg/日治疗4周使VTE患者ETP平均降低10.4%、峰值平均降低5%。
  • 非他汀组ETP自基線升高,瑞舒伐他汀组ETP降低,组间变化均值为-120.24 nm*min。
  • ETP和峰值降低在心血管危险因素及无诱因VTE亚组中更明显。

核心结论

  • 瑞舒伐他汀可降低既往VTE患者的凝血酶生成潜力。

研究设计与样本

  • START试验为随机对照试验,纳入既往VTE并在停用抗凝后的患者,随机分为瑞舒伐他汀20 mg/日治疗4周组与无干预组。
  • 共126例瑞舒伐他汀使用者与119例非使用者,平均年龄58岁,61%为男性,49%有无诱因VTE,75%有心血管危险因素。
  • 基线与研究结束时采集血浆样本,采用凝血酶生成试验分析。

主要发现

  • 非他汀组ETP自基线至研究结束平均升高97.22 nm*min(95%CI 40.92-153.53),瑞舒伐他汀组平均降低24.94 nm*min(95%CI -71.81至21.93)。
  • 两组ETP变化均值为-120.24 nm*min(95%CI -192.97至-47.51),瑞舒伐他汀使ETP降低10.4%。
  • 非他汀组凝血酶峰值平均升高20.69 nm(95%CI 9.80-31.58),瑞舒伐他汀组平均升高8.41 nm(95%CI -0.86至17.69)。
  • 两组峰值变化均值为-11.88 nm(95%CI -26.11至2.35),瑞舒伐他汀使峰值降低5%。
  • 其他凝血酶生成参数无实质变化;ETP和峰值降低在心血管危险因素及无诱因VTE亚组中更明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials The role of statins in hemostasis and venous thromboembolism (VTE) prophylaxis is not clear. This trial assessed whether rosuvastatin use affects thrombin generation in patients with VTE. Endogenous thrombin potential and peak were decreased by 10% and 5% with rosuvastatin therapy. These results provide basis for trials on the efficacy of statins in reducing recurrent VTE risk. SUMMARY: Background Statin therapy could form an alternative prophylactic treatment for venous thromboembolism (VTE) if statins are proven to downregulate hemostasis and prevent recurrent VTE, without increasing bleeding risk. Objectives The STAtins Reduce Thrombophilia (START) trial investigated whether statin affects coagulation in patients with prior VTE. Patients/methods After anticoagulation withdrawal, patients were randomized to rosuvastatin 20 mg day-1 for 4 weeks or no intervention. Plasma samples taken at baseline and at the end of the study were analyzed employing thrombin generation assay. Results and conclusions The study comprised 126 rosuvastatin users and 119 non-users. Mean age was 58 years, 61% were men, 49% had unprovoked VTE and 75% had cardiovascular (CV) risk factors. Endogenous thrombin potential (ETP) increased from baseline to end of study in non-statin users (mean 97.22 nm*min; 95% CI, 40.92-153.53) and decreased in rosuvastatin users (mean -24.94 nm*min; 95% CI, -71.81 to 21.93). The mean difference in ETP change between treatments was -120.24 nm*min (95% CI, -192.97 to -47.51), yielding a 10.4% ETP reduction by rosuvastatin. The thrombin peak increased in both non-statin (mean 20.69 nm; 95% CI, 9.80-31.58) and rosuvastatin users (mean 8.41 nm; 95% CI -0.86 to 17.69). The mean difference in peak change between treatments was -11.88 nm (95% CI, -26.11 to 2.35), yielding a 5% peak reduction by rosuvastatin. Other thrombin generation parameters did not change substantially. The reduction in ETP and peak by rosuvastatin was more pronounced in the subgroups of participants with CV risk factors and with unprovoked VTE. We conclude that rosuvastatin reduces thrombin generation potential in patients who had VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Orsi FA, Biedermann JS, Kruip MJHA, et al. Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. J Thromb Haemost. 2019. PMID: 30565854. doi:10.1111/jth.14364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。